
Product Data Sheet

Product Name: Doxefazepam

Cat. No.: GC63590

Chemical Properties

Cas. No. 40762-15-0

Formula $C_{17}H_{14}ClFN_2O_3$ M.Wt 348.76

Solubility Storage Store at -20°C

General tips For obtaining a higher solubility, please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT, or blue ice upon request.

Structure

Background

Doxefazepam is a benzodiazepine derivative. It possesses anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant properties.

Groups of 50 male and 50 female Sprague-Dawley rats are given food containing sufficient Doxefazepam, a benzodiazepine derivative, to ensure intakes of 0, 3, 10, or 30 mg/kg/day. Rats are treated for 104 weeks and then euthanized. An extensive autopsy is performed on those animals that died intercurrently and on euthanized animals. The chronic administration of Doxefazepam does not influence the survival of the rats. A significant linear trend in the incidence of hepatocellular neoplasms, primarily benign, is observed in the female treated groups. This higher incidence is not associated to a higher occurrence of focal hyperplasia or other preneoplastic lesions in treated rats. The brain, a target organ for the pharmacological activity of Doxefazepam, is carefully examined to search for microscopic foci of proliferative cells. A total of 12 and 6 malignant gliomas are observed in male and female rats, respectively; only two are noticed at autopsy. These tumors are mainly of the oligodendroglioma type commonly found in aged rats[1]. Doxefazepam is investigated in a series of toxicological studies. Oral LD50 values are greater than 2000 mg/kg in mice, rats and dogs, while endoperitoneal LD50 values are 746 and 544 mg/kg in the mice and rats, respectively,

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

and greater than 1000 mg/kg in the dogs[2].

[1]. Borelli G, et al. Carcinogenicity study of doxefazepam administered in the diet to Sprague-Dawley rats. *Fundam Appl Toxicol.* 1990 Jul;15(1):82-92.

[2]. Bertoli D, et al. Toxicological evaluations of the benzodiazepine doxefazepam. *Arzneimittelforschung.* 1989 Apr;39(4):480-4.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA